急诊尿激酶静脉溶栓对急性心肌梗死的临床治疗价值研究

目的：探讨尿激酶静脉溶栓治疗对急性心肌梗死的临床应用价值。方法：选取本院2004～2009年采用尿激酶静脉溶栓进行急性心肌梗死治疗的117例患者,按溶栓距发病时间6 h为界限,分为观察组和对照组,对两组患者的治疗情况进行总结。结果：观察组中血管再通率达84.7%,高于对照组53.4%的血管再通率。观察组中仅有2例死亡,对照组8例死亡,两组比较差异有统计学意义,χ2=13.45,P〈0.01。结论：尿激酶静脉溶栓对急性心肌梗死的治疗有较好的临床效果,尽快进行尿激酶静脉溶栓治疗可大幅度提高血管再通率,降低死亡率,使患者生命安全得到更好的保障。

Value of emergency intravenous thrombolysis with urokinase for treatment of acute myocardial infarction

Objective： To investigate the clinical applications value of urokinase thrombolytic therapy for acute myocardial infarction.Methods： To select 117 acute myocardial infarction patients treated by urokinase intravenous thrombolysis from 2004 to 2009 in our hospital.Thrombolysis to the time of onset was 6 hours as the limit,all patients were divided into observation group and control group,to summarize the treatment of two groups.Results： The rate of recanalization in observation group（84.7%） was higher than control group（53.4%）.And only 2 deaths in observation group,8 deaths in control group,the number of deaths was also less than the control group,differences were significant between the two groups,χ2= 13.45,P0.01.Conclusion： Urokinase thrombolytic therapy of acute myocardial infarction have better clinical results,as soon as possible urokinase thrombolytic therapy can greatly improve the recanalization rate,lower mortality,so that patients receive better protection of life safety.